Needham sees H2 2015 approval for Acadia's pimavanserin in PDP

Sentiment turns sour on Acadia Pharmaceuticals (ACAD -4.7%) following Tuesday's Q2 report.

Undeterred is Needham's Alan Carr who lifts his price target on the shares to $26 (from $16) citing a likely H2 2015 approval for pimavanserin in Parkinson's Disease Psychosis.

From other sites
Comments (1)
  • JamesBarb
    , contributor
    Comment (1) | Send Message
    ACAD will be the only ones out with the cure, this means that there will be no competition, now is an extremely good time to get your feet wet wether your in it for a swing trade, or your long. Definitely money to be made with ACAD
    8 Aug 2013, 03:55 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs